# OnCo record acral-melanoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/acral-melanoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "acral-melanoma" ;
  schema:name "Acral melanoma"@en ;
  schema:alternateName "Acral lentiginous melanoma"@en, "Melanoma of the palms, soles and nail beds"@en, "Subungual melanoma"@en ;
  schema:description "Acral melanoma grows on the soles, palms or under a nail, places without sun exposure, and it is the commonest melanoma in people with darker skin. It is often mistaken for a wart, bruise or fungal nail and so found late; treatment follows skin melanoma, but immunotherapy works less often because the tumour carries fewer mutations."@en ;
  schema:url <https://onco.cc/cancers/acral-melanoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acral_lentiginous_melanoma> ;
  schema:citation <https://doi.org/10.1016/j.annonc.2020.05.031>, <https://en.wikipedia.org/wiki/Acral_lentiginous_melanoma> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/mucosal-melanoma/>, <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/stage-iii-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/dermoscopy-ai/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kit/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/mek/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/tunlametinib/>, <https://onco.cc/drugs/palbociclib/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/breslow-thickness/>, <https://onco.cc/terms/ulceration-melanoma/> ;
  onco:pipeline <https://onco.cc/drugs/tunlametinib/>, <https://onco.cc/trials/nct06008106/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/trials/seacraft-2/>, <https://onco.cc/drugs/lifileucel/> ;
  onco:standardOfCare <https://onco.cc/technologies/dermoscopy-ai/>, <https://onco.cc/technologies/skin-cancer-screening/>, <https://onco.cc/terms/wide-local-excision/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/terms/breslow-thickness/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/trials/nadina/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/tunlametinib/>, <https://onco.cc/drugs/palbociclib/> .